| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | thalidomide | CTRPv2 | pan-cancer | AAC | 0.14 | 0.005 |
| mRNA | LE-135 | CTRPv2 | pan-cancer | AAC | 0.098 | 0.005 |
| mRNA | spautin-1 | CTRPv2 | pan-cancer | AAC | 0.094 | 0.01 |
| mRNA | ML050 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | BMS-195614 | CTRPv2 | pan-cancer | AAC | 0.093 | 0.01 |
| mRNA | vorinostat:navitoclax (4:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.01 |
| mRNA | YM-155 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | paclitaxel | GDSC1000 | pan-cancer | AAC | -0.12 | 0.01 |